News
-
-
-
PRESS RELEASE
Jaguar Health Satisfies Conditions for Receipt of Non-Dilutive $2 Million Holdback Payment from Future Pak for Commercial License to Mytesi and Canalevia-CA1
Jaguar Health receives $16M upfront payment in U.S. license agreement with Future Pak for crofelemer drugs. Presentation at ESPGHAN 2026 reveals positive results of crofelemer therapy for pediatric IF -
-
-
-
-
-
PRESS RELEASE
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)
Jaguar announces compassionate use of crofelemer in EU for infant with IF due to MVID. Ongoing trials show promising results in reducing PS in pediatric patients for over a year -
